Patents Assigned to Collagen Corporation
-
Patent number: 5219576Abstract: Collagen implants that are useful as wound healing matrices are characterized by being formed of collagen fibrils that are not chemically cross-linked, and having a bulk density of 0.01 to 0.3 g/cm.sup.3 and a pore population in which at least about 80% of the pores have an average pore size of 35 to 250 microns. The implants are capable of promoting connective tissue deposition, angiogenesis, reepithelialization, and fibroplasia. The wound healing matrix also serves as an effective sustained delivery system for bioactive agents.Type: GrantFiled: December 3, 1991Date of Patent: June 15, 1993Assignee: Collagen CorporationInventors: George H. Chu, Yasushi Ogawa, John M. McPherson, George Ksander, Bruce Pratt, Diana Hendricks, Hugh McMullin
-
Patent number: 5207710Abstract: Stress-bearing prostheses for replacement or partial replacement of stress-bearing bone are fixed in place by bony ingrowth by providing a stress-bearing member having a porous region in combination with an osteogenic factor extract or a purified osteogenic inductive protein, optionally in combination with a TGF-beta cofactor, in a pharmaceutically acceptable carrier. The carrier is preferably either a collagen composition or a ceramic.Type: GrantFiled: January 10, 1992Date of Patent: May 4, 1993Assignee: Collagen CorporationInventors: George H. Chu, Rosa Armstrong, Robert Chang
-
Patent number: 5204382Abstract: Injectable implant compositions comprise a biocompatible ceramic matrix present in a fluid carrier, where the ceramic matrix comprises particles having a size distribution in the range from 50 .mu.m to 250 .mu.m. Optionally, the compositions may further comprise collagen, where the relative amounts of collagen and ceramic matrix at least partly determine the physical properties of implants formed by injecting the compositions. The fluid carrier is an aqueous buffered medium, typically including an organic polymer base material when there is no collagen present in the composition. The compositions are particularly suitable for repair and augmentation of soft and hard tissues by injection.Type: GrantFiled: July 27, 1992Date of Patent: April 20, 1993Assignee: Collagen CorporationInventors: Donald G. Wallace, Hugh McMullin, George Chu
-
Patent number: 5162430Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.Type: GrantFiled: November 14, 1989Date of Patent: November 10, 1992Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5123925Abstract: The present invention is a method for treating bony defects. The method involves contacting the bony defect with a formable composition and allowing the formable composition to solidify. The formable composition is comprised of 2-40% of reconstituted fibrillar atelopeptide collagen and 60-98% calcium phosphate mineral by weight exclusive of moisture. After the formable composition is placed in intimate contact with the bony defect, it is allowed to solidify until it acquires an additional characteristic selected from the group consisting of a compressive modulus of at 10 N/cm.sup.2 or a tensile strength of at least 1 N/cm.sup.2. The method can be used to repair a variety of bony defects such as bone non-union, fresh fractures, periodontal bony pockets, tooth extraction sockets and jaw cysts. Further, the composition can be used to augment an alveolar ridge.Type: GrantFiled: January 29, 1991Date of Patent: June 23, 1992Assignee: Collagen CorporationInventors: Thomas L. Smestad, Daniel Prows, George H. Chu, Diana M. Hendericks, Debera Brown
-
Patent number: 5110604Abstract: Collagen implants that are useful as wound healing matrices are characterized by being formed of collagen fibrils that are not chemically cross-linked, and having a bulk density of 0.01 to 0.3 g/cm.sup.3 and a pore population in which at least about 80% of the pores have an average pore size of 35 to 250 microns. The implants are capable of promoting connective tissue deposition, angiogenesis, reepithelialization, and fibroplasia. The wound healing matrix also serves as an effective sustained delivery system for bioactive agents.Type: GrantFiled: December 19, 1990Date of Patent: May 5, 1992Assignee: Collagen CorporationInventors: George H. Chu, Yasushi Ogawa, John M. McPherson, George Ksander, Bruce Pratt, Diana Hendricks, Hugh McMullin
-
Patent number: 5108436Abstract: Stress-bearing prostheses for replacement or partial replacement of stress-bearing bone are fixed in place by bony ingrowth by providing a stress-bearing member having a porous region in combination with an osteogenic factor extract or a purified osteogenic inductive protein, optionally in combination with a TGF-beta cofactor, in a pharmaceutically acceptable carrier. The carrier is preferably either a collagen composition or a ceramic.Type: GrantFiled: November 23, 1988Date of Patent: April 28, 1992Assignee: Collagen CorporationInventors: George H. Chu, Rosa Armstrong, Robert Chang
-
Patent number: 5071351Abstract: The dental implant system of the present invention has a decreased surface contact angle and includes a biocompatible titanium implant which has been treated by the plasma cleaning and sterilization process of the present invention.An implant that has experienced plasma cleaning and sterilizing has improved retentive abilities over traditionally cleaned implants. The surface of the implant is now free of all organic debris, has increased wettability, contacts more bone-forming cells upon placement, and has stronger bonds between the metal surface and the bone-forming liquid cells. As a result, the implant becomes more intimately involved with the surrounding bone and tissue structure.The implant is comprised of an inert, biocompatible titanium material that is designed of such dimensions and angulations to maximize contact the bone cells and subsequently attach a well-suited mechanical prosthetic system to it.Type: GrantFiled: June 3, 1988Date of Patent: December 10, 1991Assignee: Collagen CorporationInventors: Ralph E. Green, Jr., Ronald H. Jones, Leland J. Peters, Peter J. Withol
-
Patent number: 5035715Abstract: A biocompatible collagen/mineral composition which comprises a mixture of 2-40% reconstituted fibrillar atelopeptide collagen and 60-98% calcium phosphate mineral by weight, exclusive of water, is disclosed. The composition has a sterility assurance factor of at least as low as 10.sup.-6 and either a compressive modulus of at least 10 N/cm.sup.-2 or a tensile strength of about 3-12 N/cm.sup.-2.Type: GrantFiled: May 24, 1989Date of Patent: July 30, 1991Assignee: Collagen CorporationInventors: Thomas L. Smestad, Daniel Prowse, George H. Chu, Diana M. Hendricks
-
Patent number: 5024841Abstract: Collagen implants that are useful as wound healing matrices are characterized by being formed of collagen fibrils that are not chemically cross-linked, and having a bulk density of 0.01 to 0.3 g/cm.sup.3 and a pore population in which at least about 80% of the pores have an average pore size of 35 to 250 microns. The implants are capable of promoting connective tissue deposition, angiogenesis, reepithelialization, and fibroplasia. The wound healing matrix also serves as an effective sustained delivery system for bioactive agents.Type: GrantFiled: June 30, 1988Date of Patent: June 18, 1991Assignee: Collagen CorporationInventors: George H. Chu, Yasushi Ogawa, John M. McPherson, George Ksander, Bruce Pratt, Diana Hendricks, Hugh McMullin
-
Patent number: 5008240Abstract: Inflammation, acute and/or chronic, is treated with a CIF (TGF-.beta.). The CIF may be administered locally or systemically, depending upon the indication, and does not require coadministration or activator or cofactor for efficacy.Type: GrantFiled: August 9, 1988Date of Patent: April 16, 1991Assignee: Collagen CorporationInventors: Hanne Bentz, Larry Ellingsworth, Rosa Armstrong
-
Patent number: 5001169Abstract: A composition suitable for inductive bone implants is disclosed. The composition comprises a purified form of osteogenic factor in admixture with a carrier having a percentage of mineral carrier. The resulting implants are sufficiently hypoimmunogenic to be effective when implanted in xenogeneic hosts.Type: GrantFiled: January 6, 1986Date of Patent: March 19, 1991Assignee: Collagen CorporationInventors: Ranga Nathan, Saeid Seyedin, Karl Piez, Hanne Bentz
-
Patent number: 4992226Abstract: A process for coating the pores of a mineral matrix with collagen by pumping collagen through the molded matrix is disclosed. The resulting coated matrix can be used as a prosthesis in bone repair.Type: GrantFiled: September 16, 1988Date of Patent: February 12, 1991Assignee: Collagen CorporationInventors: Karl A. Piez, Bruce B. Pharriss, George H. Chu, Thomas L. Smestad, Diana Hendricks
-
Patent number: 4971952Abstract: Inflammation, acute and/or chronic, is treated with a CIF (TGF-beta). The CIF may be administered locally or systemically, depending upon the indication, and does not require coadministration of activator or cofactor for efficacy.Type: GrantFiled: October 27, 1988Date of Patent: November 20, 1990Assignee: Collagen CorporationInventors: Hanne Bentz, Larry Ellingsworth, Rosa Armstrong
-
Patent number: 4959205Abstract: Mild dermal inflammation, such as mild eczema and seborrhea, is treated by daily application of a composition comprising 0.25%-0.5% hydrocortisone, a protective amount of a sunscreen agent, and a pharmaceutically acceptable carrier.Type: GrantFiled: March 23, 1989Date of Patent: September 25, 1990Assignee: Collagen CorporationInventors: Maureen Brunner, Howard Palefsky
-
Patent number: 4950483Abstract: Collagen implants that are useful as wound healing matrices are characterized by being formed of collagen fibrils that are not chemically cross-linked, and having a bulk density of 0.01 to 0.3 g/cm.sup.3 and a pore population in which at least about 80% of the pores have an average pore size of 35 to 250 microns. The implants are capable of promoting connective tissue deposition, angiogenesis, reepithelialization, and fibroplasia. The wound healing matrix also serves an an effective sustained delivery system for synergistic combinations of FGF and TGF-B.Type: GrantFiled: December 16, 1988Date of Patent: August 21, 1990Assignee: Collagen CorporationInventors: George Ksander, Yasushi Ogawa
-
Patent number: 4888366Abstract: An improved process for the preparation of mineral/collagen/OF (osteogenic factor) inductive implants for bone repair utilizes drying, under ambient pressure conditions, a suspension of 75-95% mineral particles, 5-25% collagen, and an effective amount of OF, such as 0.5-4% partially purified OFE or its equivalent wherein the concentration of collagen in the suspension subjected to drying is 30-100 mg/ml. The resulting implants are improved. They are homogeneous in composition and have a high compressive modulus as well as containing OF in a biologically active and available form.Type: GrantFiled: September 25, 1987Date of Patent: December 19, 1989Assignee: Collagen CorporationInventors: George Chu, Ranga Nathan, Saeid Seyedin
-
Patent number: 4865602Abstract: A process for sterilization of collagen/mineral compositions using .gamma. radiation is conducted under conditions which produce a product of desired handling and biocompatibility properties.Type: GrantFiled: November 6, 1986Date of Patent: September 12, 1989Assignee: Collagen CorporationInventors: Thomas L. Smestad, Daniel Prows, George H. Chu, Diana M. Hendricks
-
Patent number: 4863732Abstract: Aqueous suspensions of fibrillar atelopeptide collagen and osteogenic factor are effective injectable preparations for the repair of bone defects.Type: GrantFiled: December 16, 1987Date of Patent: September 5, 1989Assignee: Collagen CorporationInventors: Ranga Nathan, Andrea Thompson, Saeid Seyedin
-
Patent number: 4843063Abstract: Two proteins that are found in bone and that have in vivo chondrogenic/osteogenic activity in combination with a co-factor are described. Both proteins also were active in combination with EGF in the in vitro TGF-.beta. assay. Each has a molecular weight of approximately 26,000 daltons by SDS-PAGE. Each is reduced to a single polypeptide indicating that the proteins are probably homodimers. One has an N-terminal sequence identical to that of human placenta-derived TGF-.beta. whereas the other has an N-terminal sequence that is different from that of TGF-.beta. derived from human placenta. The two proteins may be purified to hmogeneity using RP-HPLC or acetic acid-urea gel electrophoresis.Type: GrantFiled: June 8, 1988Date of Patent: June 27, 1989Assignee: Collagen CorporationInventors: Saeid Seyedin, Thomas Thomas, Hanne Bentz, Larry Ellingsworth, Rosa Armstrong